

Nicola Ferri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1868106/nicola-ferri-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

136
papers

3,975
citations

34
h-index

56
g-index

178
ext. papers

4,770
ext. citations

4.7
avg, IF

5.61
L-index

#	Paper	IF	Citations
136	Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications.. <i>Cardiovascular Research</i> , 2022 ,	9.9	4
135	Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents.. <i>Bioorganic Chemistry</i> , 2022 , 121, 105686	5.1	0
134	Mitochondrial depletion of glutaredoxin 2 induces metabolic dysfunction-associated fatty liver disease in mice.. <i>Redox Biology</i> , 2022 , 51, 102277	11.3	1
133	Effect of REL-1017 (Esmethadone) on Cholesterol, Triglycerides, PCSK9, and hs-CRP in a Phase 2a Double-Blind Randomized Trial in Patients with MDD.. <i>CNS Spectrums</i> , 2022 , 27, 246-247	1.8	
132	The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. <i>Biology</i> , 2022 , 11, 693	4.9	
131	Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. <i>Pharmaceutics</i> , 2022 , 14, 1120	6.4	1
130	Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 334-345	6.4	5
129	Lipid Lowering Drugs: Present Status and Future Developments. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 17	6	9
128	PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
127	Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact. <i>American Journal of Pathology</i> , 2021 , 191, 1385-1397	5.8	26
126	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021 , 67, 40-52	8.5	14
125	Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study. <i>Biomedicines</i> , 2021 , 9,	4.8	2
124	DrugDrug Interaction with DOACs 2021 , 41-69		
123	Phage display for targeting PCSK9. <i>EBioMedicine</i> , 2021 , 65, 103267	8.8	
122	Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
121	Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance. <i>Cardiovascular Diabetology</i> , 2020 , 19, 187	8.7	14
120	Naturally Occurring PCSK9 Inhibitors. <i>Nutrients</i> , 2020 , 12,	6.7	14

119	Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies. <i>European Heart Journal Supplements</i> , 2020 , 22, E64-E67	1.5	4
118	Clinical Pharmacology of Statins: an Update. <i>Current Atherosclerosis Reports</i> , 2020 , 22, 26	6	13
117	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. <i>Drugs</i> , 2020 , 80, 1065-1083	12.1	13
116	l-Arginine prevents inflammatory and pro-calcific differentiation of interstitial aortic valve cells. <i>Atherosclerosis</i> , 2020 , 298, 27-35	3.1	10
115	Cytotoxic performances of new anionic cyclometalated Pt(II) complexes bearing chelated O [^] O ligands. <i>Applied Organometallic Chemistry</i> , 2020 , 34, e5455	3.1	2
114	Exploring the Anticancer Potential of Diiron Bis-cyclopentadienyl Complexes with Bridging Hydrocarbyl Ligands: Behavior in Aqueous Media and In Vitro Cytotoxicity. <i>Organometallics</i> , 2020 , 39, 645-657	3.8	22
113	Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line. <i>Nutrients</i> , 2020 , 12,	6.7	6
112	Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. <i>Pharmacological Research</i> , 2020 , 153, 104653	10.2	28
111	and Ameliorate Liver Function by Reducing Diet-Induced Steatosis in Rats. <i>Marine Drugs</i> , 2020 , 18,	6	9
110	Clinical approach to the inflammatory etiology of cardiovascular diseases. <i>Pharmacological Research</i> , 2020 , 159, 104916	10.2	34
109	Angiotensin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 2251-2254	3.9	6
108	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
107	Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 2372-2378	4.5	3
106	Lipoprotein(a) and PCSK9 inhibition: clinical evidence. <i>European Heart Journal Supplements</i> , 2020 , 22, L53-L56	1.5	8
105	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3. <i>American Journal of Pathology</i> , 2020 , 190, 2226-2236	5.8	12
104	Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. <i>Atherosclerosis</i> , 2020 , 309, 39-46	3.1	9
103	Himalayan Nettle as a Candidate Ingredient for Pharmaceutical and Nutraceutical Applications-Phytochemical Analysis and In Vitro Bioassays. <i>Molecules</i> , 2020 , 25,	4.8	8
102	Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019 , 29, 1245-1253	4.5	6

101	Identification of the first enantiopure Rac1-Tiam1 protein-protein interaction inhibitor and its optimized synthesis phosphine free remote group directed hydroarylation. <i>MedChemComm</i> , 2019 , 10, 310-314	5	3
100	Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 120	5.3	30
99	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 930-949	3.9	44
98	Monofunctional PtII Complexes Based on 8-Aminoquinoline: Synthesis and Pharmacological Characterization. <i>European Journal of Inorganic Chemistry</i> , 2019 , 2019, 3389-3395	2.3	8
97	Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 578-588	3.9	25
96	PCSK9 as a Positive Modulator of Platelet Activation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 952-954	15.1	33
95	PCSK9 induces a pro-inflammatory response in macrophages. <i>Scientific Reports</i> , 2018 , 8, 2267	4.9	104
94	Present therapeutic role of cholesteryl ester transfer protein inhibitors. <i>Pharmacological Research</i> , 2018 , 128, 29-41	10.2	35
93	PCSK9 antagonists and inflammation. <i>Atherosclerosis</i> , 2018 , 268, 235-236	3.1	12
92	From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 1843-1851	3.9	11
91	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. <i>Annals of Medicine</i> , 2018 , 50, 461-484	1.5	18
90	Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects. <i>Journal of Cardiovascular Development and Disease</i> , 2018 , 5,	4.2	25
89	The Brown Algae <i>Fucus vesiculosus</i> and <i>Ascophyllum nodosum</i> Reduce Metabolic Syndrome Risk Factors: A Clinical Study. <i>Natural Product Communications</i> , 2018 , 13, 1934578X1801301	0.9	6
88	PCSK9 Involvement in Aortic Valve Calcification. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3225-3227	15.1	21
87	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018 , 1863, 991-997	5	9
86	Bococizumab for the treatment of hypercholesterolaemia. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 237-243	5.4	16
85	In vitro anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 1907-1913	3.4	22
84	Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017 , 32, 337-344	5.6	7

83	A field-based disparity analysis of new 1,2,5-oxadiazole derivatives endowed with antiproliferative activity. <i>Chemical Biology and Drug Design</i> , 2017 , 90, 820-839	2.9	9
82	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	47
81	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2660-2669	5.6	30
80	Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. <i>Atherosclerosis</i> , 2017 , 256, 1-6	3.1	69
79	Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. <i>Pharmacological Research</i> , 2017 , 122, 96-104	10.2	9
78	PPAR- δ agonists are still on the rise: an update on clinical and experimental findings. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 593-602	5.9	34
77	The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017 , 361, 398-407	4.7	37
76	An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties. <i>European Journal of Medicinal Chemistry</i> , 2017 , 131, 196-206	6.8	26
75	Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. <i>Therapeutics and Clinical Risk Management</i> , 2017 , 13, 1555-1562	2.9	14
74	New sulfurated derivatives of cinnamic acids and rosmarinic acid as inhibitors of STAT3 and NF- κ B transcription factors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017 , 32, 1012-1028	5.6	4
73	Tuning the cytotoxicity of ruthenium(II) para-cymene complexes by mono-substitution at a triphenylphosphine/phenoxydiphenylphosphine ligand. <i>Dalton Transactions</i> , 2017 , 46, 16589-16604	4.3	34
72	The small heat shock protein B8 (HSPB8) modulates proliferation and migration of breast cancer cells. <i>Oncotarget</i> , 2017 , 8, 10400-10415	3.3	33
71	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 315-320	4.3	25
70	Peptide modulators of Rac1/Tiam1 protein-protein interaction: An alternative approach for cardiovascular diseases. <i>Peptide Science</i> , 2017 , 110, e23089	3	16
69	Development of poly(lactide-co-glycolide) nanoparticles functionalized with a mitochondria penetrating peptide. <i>Journal of Peptide Science</i> , 2017 , 23, 182-188	2.1	7
68	Pharmacokinetics interactions of monoclonal antibodies. <i>Pharmacological Research</i> , 2016 , 111, 592-599	10.2	58
67	Disruption of ArhGAP15 results in hyperactive Rac1, affects the architecture and function of hippocampal inhibitory neurons and causes cognitive deficits. <i>Scientific Reports</i> , 2016 , 6, 34877	4.9	23
66	Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. <i>Journal of Biological Chemistry</i> , 2016 , 291, 3508-19	5.4	70

65	Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. <i>Translational Research</i> , 2016 , 173, 19-29	11	37
64	Liver fat accumulation is associated with circulating PCSK9. <i>Annals of Medicine</i> , 2016 , 48, 384-91	1.5	78
63	Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. <i>Endocrine</i> , 2016 , 54, 588-601	4	48
62	PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. <i>Atherosclerosis</i> , 2016 , 253, 214-224	3.1	53
61	Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 579-92	7	29
60	Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. <i>Bioorganic and Medicinal Chemistry</i> , 2015 , 23, 2538-47	3.4	18
59	Dipeptide Nanotubes Containing Unnatural Fluorine-Substituted (2,3)-Diarylamino Acid and L-Alanine as Candidates for Biomedical Applications. <i>Organic Letters</i> , 2015 , 17, 4468-71	6.2	38
58	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 186-97	7	19
57	Naturally occurring PDGF receptor inhibitors with potential anti-atherosclerotic properties. <i>Vascular Pharmacology</i> , 2015 , 70, 1-7	5.9	18
56	Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015 , 16, 284-91	3	4
55	Clinical evidence of statin therapy in non-dyslipidemic disorders. <i>Pharmacological Research</i> , 2014 , 88, 20-30	10.2	16
54	2-Amino-3-(phenylsulfanyl)norbornane-2-carboxylate: an appealing scaffold for the design of Rac1-Tiam1 protein-protein interaction inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 2953-62	8.3	26
53	Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014 , 24, 2924-7	2.9	15
52	Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. <i>Drugs</i> , 2013 , 73, 1681-709	12.1	92
51	Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 211-9	3.9	8
50	Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. <i>Pharmacology & Therapeutics</i> , 2013 , 138, 470-84	13.9	127
49	Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in Pt(II) complexes on human carcinoma cell lines: a comparative study with cisplatin. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 2379-2386	3.4	20
48	3-Aryl-N-aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides: a new class of selective Rac inhibitors. <i>MedChemComm</i> , 2013 , 4, 537	5	21

47	Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts. <i>Cellular Signalling</i> , 2013 , 25, 1044-53	4.9	10
46	Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors. <i>Journal of Cardiovascular Pharmacology</i> , 2013 , 62, 425-35	3.1	24
45	AMP-activated protein kinase and the control of smooth muscle cell hyperproliferation in vascular disease. <i>Vascular Pharmacology</i> , 2012 , 56, 9-13	5.9	16
44	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. <i>Atherosclerosis</i> , 2012 , 220, 381-6	3.1	161
43	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2012 , 428, 230-3	3.4	16
42	Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor. <i>Cardiovascular Research</i> , 2012 , 95, 366-74	9.9	24
41	Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. <i>Scientifica</i> , 2012 , 2012, 927352	2.6	8
40	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. <i>Atherosclerosis</i> , 2011 , 214, 331-7	3.1	32
39	Muscle cells and motoneurons differentially remove mutant SOD1 causing familial amyotrophic lateral sclerosis. <i>Journal of Neurochemistry</i> , 2011 , 118, 266-80	6	46
38	17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. <i>Neurobiology of Disease</i> , 2011 , 41, 83-95	7.5	54
37	Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 5291-9	3.4	23
36	Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 5408-12	2.9	19
35	Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011 , 12, 469-74	3	24
34	Fibrillar collagen inhibits cholesterol biosynthesis in human aortic smooth muscle cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 1631-7	9.4	1
33	Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 328, 419-25	4.7	46
32	New Ras CAAX mimetics: design, synthesis, antiproliferative activity, and RAS prenylation inhibition. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 5500-4	2.9	11
31	Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009 , 19, 6298-302	2.9	20
30	Differential Processing of {alpha}- and {beta}-Defensin Precursors by Matrix Metalloproteinase-7 (MMP-7). <i>Journal of Biological Chemistry</i> , 2009 , 284, 8301-11	5.4	45

29	Virtual screening approach for the identification of new Rac1 inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009 , 52, 4087-90	8.3	86
28	Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. <i>Molecular Pharmacology</i> , 2008 , 74, 144-53	4.3	16
27	Inhibition of Smooth Muscle Cell Migration and Proliferation by Statins. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008 , 8, 122-140		4
26	Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 1691-704	3.4	23
25	Peptidomimetic inhibitors of farnesyltransferase with high in vitro activity and significant cellular potency. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 6192-6	2.9	20
24	Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 1043-9	4	37
23	Are pleiotropic effects of statins real?. <i>Vascular Health and Risk Management</i> , 2007 , 3, 611-3	4.4	21
22	Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen. <i>Circulation Research</i> , 2006 , 98, 1490-7	15.7	36
21	Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. <i>Current Opinion in Lipidology</i> , 2006 , 17, 495-501	4.4	19
20	Isothiazoles. Part XV. A mild and efficient synthesis of new antiproliferative 5-sulfanylsubstituted 3-alkylaminoisothiazole 1,1-dioxides. <i>European Journal of Medicinal Chemistry</i> , 2006 , 41, 675-82	6.8	10
19	Lipid-modified proteins as biomarkers for cardiovascular disease: a review. <i>Biomarkers</i> , 2005 , 10, 219-37	2.6	24
18	Isothiazole dioxide derivative 6n inhibits vascular smooth muscle cell proliferation and protein farnesylation. <i>Biochemical Pharmacology</i> , 2005 , 70, 1735-43	6	7
17	Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. <i>Journal of Lipid Research</i> , 2005 , 46, 1081-92	6.3	128
16	Beyond the endothelium: NF-kappaB regulation of smooth muscle function. <i>Circulation Research</i> , 2004 , 94, 706-8	15.7	23
15	Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioliomyomatosis. <i>American Journal of Pathology</i> , 2004 , 164, 1575-85	5.8	142
14	Cleavage of focal adhesion kinase in vascular smooth muscle cells overexpressing membrane-type matrix metalloproteinases. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 839-44	9.4	20
13	An NF-kappaB-dependent transcriptional program is required for collagen remodeling by human smooth muscle cells. <i>Journal of Biological Chemistry</i> , 2003 , 278, 19757-64	5.4	28
12	Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation. <i>British Journal of Pharmacology</i> , 2003 , 138, 811-8	8.6	25

11	Fas and Fas-associated death domain protein regulate monocyte chemoattractant protein-1 expression by human smooth muscle cells through caspase- and calpain-dependent release of interleukin-1alpha. <i>Circulation Research</i> , 2003 , 93, 515-22	15.7	34
10	Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors. <i>BioTechniques</i> , 2002 , 32, 830, 832, 834 passim	2.5	39
9	Effect of S(-) perillic acid on protein prenylation and arterial smooth muscle cell proliferation. <i>Biochemical Pharmacology</i> , 2001 , 62, 1637-45	6	17
8	xIAP induces cell-cycle arrest and activates nuclear factor-kappaB : new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. <i>Circulation Research</i> , 2001 , 88, 282-90	15.7	128
7	Non-lipid-related effects of statins. <i>Annals of Medicine</i> , 2000 , 32, 164-76	1.5	269
6	Direct vascular effects of HMG-CoA reductase inhibitors. <i>Atherosclerosis</i> , 1998 , 137 Suppl, S101-9	3.1	172
5	Effect of Statins Beyond Lowering Cholesterol: Where Do We Stand?. <i>Medical Science Symposia Series</i> , 1998 , 253-265		
4	Effects of four antiepileptic drugs on sleep and waking in the rat under both light and dark phases. <i>Pharmacology Biochemistry and Behavior</i> , 1996 , 53, 559-65	3.9	12
3	Role of Isoprenoids In the Growth-Factor Signal Transduction and their Pharmacological Modulation. <i>Medical Science Symposia Series</i> , 1996 , 103-110		
2	Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylentetrazole-induced convulsions in the rat. <i>European Journal of Pharmacology</i> , 1995 , 294, 383-9	5.3	45
1	The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. <i>European Journal of Pharmacology</i> , 1993 , 235, 83-7	5.3	51